Investor Centre
Our broad clinical and preclinical pipeline in oncology and behavioural brain disorders focuses on indications including glioblastoma, neurodevelopmental disorders, addiction, anxiety, fatigue and narcolepsy.
0.21 GBX
Volume:
690,593
Market Capitalisation (m)
£4.47
TheraCryf plc Investor Presentation
Major Shareholder
| Current Shareholder | Number of shares | Percentage holding |
|---|---|---|
| JIM Nominees Limited | 79,684,473 | 15.60% |
| J. R. Kight | 34,600,000 | 6.80% |
| First Equity Limited | 130,200,000 | 6.11% |
| Rathbones Investment Management Ltd | 25,789,246 | 5.10% |
| Octopus Investments | 21,875,000 | 4.30% |
| Vulpes Investment Management Pte Ltd | 20,554,191 | 4.80% |
| Seneca Partners Limited | 16,301,456 | 3.20% |
The number of ordinary shares in issue is 2,129,622,422 all of which are in public hands. The Company does not hold any shares in Treasury.
